<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">J Thorac Dis</journal-id><journal-id journal-id-type="iso-abbrev">J Thorac Dis</journal-id><journal-id journal-id-type="pmc-domain-id">1685</journal-id><journal-id journal-id-type="pmc-domain">jtd</journal-id><journal-id journal-id-type="publisher-id">JTD</journal-id><journal-title-group><journal-title>Journal of Thoracic Disease</journal-title></journal-title-group><issn pub-type="ppub">2072-1439</issn><issn pub-type="epub">2077-6624</issn><publisher><publisher-name>AME Publications</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC11833575</article-id><article-id pub-id-type="pmcid-ver">PMC11833575.1</article-id><article-id pub-id-type="pmcaid">11833575</article-id><article-id pub-id-type="pmcaiid">11833575</article-id><article-id pub-id-type="pmid">39975759</article-id><article-id pub-id-type="doi">10.21037/jtd-2024-2243</article-id><article-id pub-id-type="publisher-id">jtd-17-01-429</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Association of statin use with 28-day mortality in the Medical Information Mart for Intensive Care IV database: a retrospective cohort study</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Kang</surname><given-names initials="C">Chen</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0009-0001-1690-0770</contrib-id><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Li</surname><given-names initials="F">Feifei</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Zhao</surname><given-names initials="H">He</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Honore</surname><given-names initials="PM">Patrick M.</given-names></name><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Dagli-Hernandez</surname><given-names initials="C">Carolina</given-names></name><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Hoshi</surname><given-names initials="T">Tomoya</given-names></name><xref rid="aff4" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Jin</surname><given-names initials="Y">Yiran</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref></contrib><aff id="aff1"><label>1</label><institution content-type="dept">Department of Pharmacy</institution>, <institution>The Second Hospital of Hebei Medical University</institution>, <addr-line>Shijiazhuang</addr-line>, <country country="cn">China</country>;</aff><aff id="aff2"><label>2</label><institution content-type="dept">Intensive Care Department, CHU UCL Namur Godinne</institution>, <institution>UCL Louvain Medical School</institution>, <addr-line>Yvoir</addr-line>, <country country="be">Belgium</country>;</aff><aff id="aff3"><label>3</label><institution content-type="dept">School of Pharmaceutical Sciences</institution>, <institution>University of S&#227;o Paulo</institution>, <addr-line>S&#227;o Paulo, SP</addr-line>, <country country="br">Brazil</country>;</aff><aff id="aff4"><label>4</label><institution content-type="dept">Department of Cardiology, Institute of Medicine</institution>, <institution>University of Tsukuba</institution>, <addr-line>Ibaraki</addr-line>, <country country="jp">Japan</country></aff></contrib-group><author-notes><fn id="afn1"><p><italic toggle="yes">Contributions:</italic> (I) Conception and design: Y Jin, C Kang; (II) Administrative support: Y Jin; (III) Provision of study materials or patients: None; (IV) Collection and assembly of data: C Kang, F Li, H Zhao; (V) Data analysis and interpretation: C Kang; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.</p></fn><corresp id="cor1"><italic toggle="yes">Correspondence to:</italic> Yiran Jin, MD. Department of Pharmacy, The Second Hospital of Hebei Medical University, 215 Heping West Road, Xinhua District, Shijiazhuang 050000, China. Email: <email xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="27500012@hebmu.edu.cn">27500012@hebmu.edu.cn</email>.</corresp></author-notes><pub-date pub-type="epub"><day>22</day><month>1</month><year>2025</year></pub-date><pub-date pub-type="ppub"><day>24</day><month>1</month><year>2025</year></pub-date><volume>17</volume><issue>1</issue><issue-id pub-id-type="pmc-issue-id">482418</issue-id><fpage>429</fpage><lpage>440</lpage><history><date date-type="received"><day>24</day><month>12</month><year>2024</year></date><date date-type="accepted"><day>08</day><month>1</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>24</day><month>01</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>19</day><month>02</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-02-21 18:26:04.557"><day>21</day><month>02</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>Copyright &#169; 2025 AME Publishing Company. All rights reserved.</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>AME Publishing Company.</copyright-holder><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p><italic toggle="yes">Open Access Statement:</italic> This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">https://creativecommons.org/licenses/by-nc-nd/4.0</ext-link>.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="jtd-17-01-429.pdf"/><abstract><sec><title>Background</title><p>Statins, acknowledged for their ability to reduce cardiovascular risk, demonstrate a variety of pleiotropic effects, including anti-inflammatory, antithrombotic, endothelial stabilizing activity and prevention of acute kidney injury (AKI) post cardiac surgery. Patients in the intensive care unit (ICU) face heightened risks of cardiovascular disease, infections, and thrombotic complications, but the effect of statin therapy on ICU mortality remains controversial. The Medical Information Mart for Intensive Care IV (MIMIC-IV) database is a publicly available intensive care medicine information database that includes data on critically ill patients admitted to the ICU at Beth Israel Deaconess Medical Center from 2008 to 2019, with a large sample size. In this retrospective cohort study, the MIMIC-IV database was used to clarify the association between statin therapy and all-cause mortality in critically ill patients. An additional aim was to compare the effect of different statin types on mortality.</p></sec><sec><title>Methods</title><p>Patients aged 18 years or older, with first-time admissions and complete data, were categorized based on their use of statins during their ICU stay. The primary outcome was 28-day mortality, analyzed through multivariable Cox regression and expressed as adjusted hazard ratios (HRs) with 95% confidence intervals (CIs). The relationship between statin therapy and 28-day mortality in ICU patients was estimated using propensity score matching (PSM) and multivariable analysis to adjust for covariates.</p></sec><sec><title>Results</title><p>Among the 50,624 enrolled patients, 30.9% were treated with statins. Compared to patients not receiving statin therapy, those on statins were older, had a higher proportion of males (62.0% <italic toggle="yes">vs</italic>. 53.1%), a greater percentage with health insurance (50.2% <italic toggle="yes">vs</italic>. 39.5%), and a higher rate of concurrent aspirin use (70.8% <italic toggle="yes">vs</italic>. 18.2%). In terms of comorbidities, patients in the statin group had higher proportions of congestive heart failure (CHF), AKI, myocardial infarction, and chronic obstructive pulmonary disease (COPD). Statin treatment in patients in the ICU was correlated with reduced 28-day all-cause mortality in the multivariate Cox analysis (statins: HR =0.66, 95% CI: 0.61&#8211;0.70; atorvastatin: HR =0.71, 95% CI: 0.66&#8211;0.78; rosuvastatin: HR =0.57, 95% CI: 0.45&#8211;0.72; simvastatin: HR =0.54, 95% CI: 0.48&#8211;0.62; other statins: HR =0.68, 95% CI: 0.56&#8211;0.83). PSM confirmed these findings (statins: HR =0.69, 95% CI: 0.63&#8211;0.75).</p></sec><sec><title>Conclusions</title><p>Statin use may correlate with a decreased risk of 28-day mortality in patients in the ICU, with simvastatin showing a more pronounced effect. The robustness of these findings remain unaffected in the subgroup analyses, sensitivity analyses, and PSM, indicating potential clinical significance. The high mortality rate among ICU patients means that any method capable of reducing mortality could have significant implications for ICU treatment.</p></sec></abstract><kwd-group kwd-group-type="author"><title>Keywords: </title><kwd>Intensive care units (ICUs)</kwd><kwd>hydroxymethylglutaryl-coenzyme A reductase inhibitors (HMG-CoA reductase inhibitors)</kwd><kwd>Medical Information Mart for Intensive Care IV (MIMIC-IV)</kwd><kwd>mortality</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><boxed-text id="ba" position="float" orientation="portrait"><caption><title>Highlight box</title></caption><sec><title>Key findings</title><p>&#8226; Through retrospective analysis of critically ill patients in the Medical Information Mart for Intensive Care IV database, it was found that statin use could potentially reduced the risk of death in patients in intensive care units (ICUs).</p><p>&#8226; Compared with other statins, simvastatin had the highest reduction of mortality among patients in the ICU.</p><p>&#8226; In patients with chronic obstructive pulmonary disorder, acute kidney injury, sepsis, or myocardial infarction, statin use was associated with reduced 28-day mortality, while the association of statin use and 28-day mortality did not differ according to sex.</p></sec><sec><title>What is known and what is new?</title><p>&#8226; Statins can lower blood cholesterol levels and prevent cardiovascular events in patients with cardiovascular disease.</p><p>&#8226; This study further confirmed the benefits of statin multipotency in treating patients in the ICU, which can potentially improve the prognosis of those with multiple diseases and perhaps reduce mortality.</p></sec><sec><title>What is the implication, and what should change now?</title><p>&#8226; The results highlight the potential effect of statins on mortality in patients in the ICU, mortality is high in severe cases, and methods to reduce mortality are meaningful for patients.</p><p>&#8226; For clinical pharmacists, this study may be useful for drug reformulation for patients in the ICU.</p><p>&#8226; Clinicians should be aware of the importance of statins and decide upon whether to add or cease statins according to the actual situation of patients and not arbitrarily.</p></sec></boxed-text><sec sec-type="intro"><title>Introduction</title><p>The hydroxymethylglutaryl-coenzyme A reductase inhibitors (HMG-CoA reductase inhibitors), commonly referred to as statins, have traditionally been used for the purpose of reducing blood cholesterol levels or preventing cardiovascular events in patients diagnosed with cardiovascular disease (<xref rid="r1" ref-type="bibr">1</xref>). Approximately 200 million patients are treated with this drug globally. These agents impede the activity of the pivotal enzyme in cholesterol synthesis, thereby diminishing cholesterol production. Simultaneously, they enhance the expression of cell surface low-density lipoprotein (LDL) receptors, accelerating the catabolism of serum LDL. Consequently, statins markedly lower levels of serum total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), and apolipoprotein B (ApoB); moderately decrease serum triglyceride (TG) levels; and elevate high-density lipoprotein cholesterol (HDL-C) levels (<xref rid="r2" ref-type="bibr">2</xref>). Beyond lipid-lowering effects, statins possess therapeutic attributes unrelated to lipid modulation. These multifaceted effects on the vascular endothelium include immunomodulatory, anti-inflammatory, and antithrombotic activity (<xref rid="r3" ref-type="bibr">3</xref>-<xref rid="r5" ref-type="bibr">5</xref>). These non-lipid-related benefits, termed the &#8220;pleiotropic effect&#8221;, may enhance the prognosis of patients across various diseases (<xref rid="r6" ref-type="bibr">6</xref>), even extending potential benefit to patients with noncardiovascular conditions such as cancer, chronic obstructive pulmonary disease (COPD), and rheumatoid arthritis (<xref rid="r7" ref-type="bibr">7</xref>). The immunomodulatory, anti-inflammatory, and antioxidant effects of statins have garnered significant attention in recent years, leading to their investigation as a host-directed therapy for the treatment of infectious diseases (<xref rid="r8" ref-type="bibr">8</xref>).</p><p>Concerning anti-inflammatory activity, the growing incidence of sepsis and related fatalities necessitates the further development of therapeutic interventions. In animal models of sepsis (<xref rid="r9" ref-type="bibr">9</xref>,<xref rid="r10" ref-type="bibr">10</xref>), statins demonstrated inhibitory effects on inflammatory mediators, potentially by disrupting isoprenoid intermediates in the mevalonate pathway. This interference allows for the upregulation of nuclear factor-&#954;B (NF-&#954;B) inhibitors, inhibiting NF-&#954;B-dependent inflammation. Statins also mitigate the cellular damage associated with endotoxins and exotoxins, reverse renal tubular hypoxia, and directly impact the renal vascular system, potentially ameliorating the acute kidney injury (AKI) induced by sepsis (<xref rid="r11" ref-type="bibr">11</xref>,<xref rid="r12" ref-type="bibr">12</xref>).</p><p>Fungi are a near ubiquitous class of eukaryotic organisms, and the prevalence of fungal infections has exhibited a substantial rise with the administration of immunosuppressive agents, radiotherapy for neoplasms,<italic toggle="yes"> in vivo </italic>tube placements, and extended stays in intensive care units (ICUs). Statins have demonstrated antifungal efficacy and can synergistically enhance the effectiveness of antifungal medications (<xref rid="r13" ref-type="bibr">13</xref>). The possible pathway mechanisms for this effect involve, first, the inhibition of farnesyl pyrophosphate (FPP) production in the mevalonate pathway by statins, which impedes ergosterol biosynthesis, a crucial component in fungal cell membranes (<xref rid="r14" ref-type="bibr">14</xref>). Second, statins may suppress the isoprenylation pathway, hindering the activation of vital cellular proteins involved in cellular respiration and iron metabolism (<xref rid="r15" ref-type="bibr">15</xref>,<xref rid="r16" ref-type="bibr">16</xref>). Third, statins may induce fungal mitochondrial dysfunction and apoptosis. Finally, the statin-induced blockade of HMG-CoA reductase can dampen fungal spore germination (<xref rid="r17" ref-type="bibr">17</xref>). These findings were not yet applied in clinical medicine.</p><p>As it relates to antithrombotic activity, venous thromboembolism, including deep vein thrombosis and pulmonary embolism, represents a frequent complication in critically ill patients, correlating with substantial morbidity and mortality. Cluster of differentiation 36 (CD36), a single-chain glycoprotein expressed on various cell surfaces, binds to platelet membrane CD36, initiating endogenous reactive oxygen species production and causing platelet activation and thrombosis (<xref rid="r18" ref-type="bibr">18</xref>). Statins can exert inhibitory effects on platelet activation and aggregation either through direct interaction with CD36 or by modulating the intracellular signaling pathway of CD36, among other pathways. Obviously, platelets are not the only player in pulmonary embolism as the classical pathway of hemostasis is playing a crucial role as well.</p><p>Patients in the ICU have a high incidence of complications such as cardiovascular diseases, severe infection, and thrombosis, and almost all patients in the ICU experience systemic inflammatory response syndromes, leading to a high mortality rate (<xref rid="r19" ref-type="bibr">19</xref>). Investigating the potentially advantageous pleiotropic effects of statins in the ICU setting could potentially yield substantial benefits for clinical practice and public health. We employed a population subset from a comprehensive public critical care database to examine the correlation between statin usage and 28-day all-cause mortality among adult patients in the ICU. We present this article in accordance with the STROBE reporting checklist (available at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://jtd.amegroups.com/article/view/10.21037/jtd-2024-2243/rc" ext-link-type="uri">https://jtd.amegroups.com/article/view/10.21037/jtd-2024-2243/rc</ext-link>).</p><sec><title>Aim</title><p>The aim of this study was to determine the relationship between statin therapy and all-cause mortality in critically ill patients and to compare the effects of different types of statins on mortality.</p></sec></sec><sec sec-type="methods"><title>Methods</title><sec><title>Data source</title><p>This investigation employed a retrospective cohort design using data derived from the MIMIC-IV database (version 1.0) (<xref rid="r20" ref-type="bibr">20</xref>). MIMIC-IV is a longitudinal, single-center database encompassing comprehensive information on patients admitted to the ICU at Beth Israel Deaconess Medical Center between 2008 and 2019. The database includes demographic details, vital signs, laboratory results, diagnostic particulars, treatment records, and instances of mortality during hospitalization. The study was conducted in accordance with the Declaration of Helsinki (as revised in 2013). We (C.K.; ID: 55395496) signed a data use agreement form and completed the Collaborative Institutional Training Initiative (CITI) exam to be authorized to access and use the database and perform data extraction and analysis.</p></sec><sec><title>Study population</title><p>Study participants comprised individuals from the database meeting the following criteria: (I) initial admission to the ICU; (II) aged &#8805;18 years; and (III) patients without missing data. Participants in the statin group were required to receive statin treatment for a minimum of 3 days after ICU admission. In our study, we divided patients into statin and non-statin groups based on inclusion and exclusion criteria, and incorporated selected covariates into propensity score matching (PSM) to ensure comparability between the two groups.</p></sec><sec><title>Outcome indicator</title><p>The primary focus was the examination of the association between statin use and 28-day mortality. Additionally, the associations of different statin types with patient mortality was ascertained. Mortality within 28 days of admission was determined using the date of death (DOS), time of admission (INTIME), and time of discharge (OUTTIME).</p></sec><sec><title>Study variables</title><p>All data were extracted from the relevant tables in the data management library pgAdmin 4.26 using Structured Query Language (SQL) language. The variables subjected to analysis included age, gender, race, type of insurance, aspirin usage, the severity of condition score, comorbidities (e.g., heart failure, kidney disease, severe liver disease, myocardial infarction, acute renal failure, COPD), and vital signs (systolic blood pressure, diastolic blood pressure, heart rate, respiratory rate). Variables such as height and body mass index were excluded due to the presence of missing data in over 50% of cases.</p></sec><sec><title>Statistical analysis</title><p>Multivariate Cox regression analysis was employed to evaluate the correlation between statin use and 28-day all-cause mortality subsequent to admission to the ICU. An extended Cox modeling approach was implemented to account for various covariates in the model. Kaplan-Meier and log-rank analyses were used to generate survival curves. Subgroup analyses were conducted with stratification based on the pertinent covariates.</p><p>The descriptive analysis involved all patients eligible for enrollment. Categorical variables are presented as percentages (%), while continuous variables are expressed as the mean and standard deviation (SD) or as the median and interquartile range (IQR), as appropriate. Variable comparisons were executed using the Chi-squared test for categorical variables, the <italic toggle="yes">t</italic>-test for normally distributed variables, and the Mann-Whitney test for skewed variables. Patients with a substantial number of missing covariates were systematically excluded, along with 296 patients with missing values, illogical entries, or exit times. In the context of observational studies, the adjustment for intergroup individual differences through propensity scores renders all confounding variables, excluding exposure/treatment factors and outcome variables, comparably equivalent. This is tantamount to a post hoc randomization approach, aligning observational study data with an approximation of random assignment. PSM was gauged using standardized mean differences (SMDs), with a threshold of &lt;0.1 considered acceptable.</p><p>All statistical analyses were carried out using R version 3.3.2 (The R Foundation of Statistical Computing) and FreeStatistics software version 1.8. A two-tailed test was employed, and statistical significance was defined as P&lt;0.05. FreeStatistics is a software package that offers an intuitive interface for common data analyses and visualizations, with R as the underlying statistical engine and its graphical user interface scripted in Python, and is designed to facilitate reproducible analyses and interactive calculations.</p></sec></sec><sec sec-type="results"><title>Results</title><sec><title>Population</title><p>A total of 76,540 records documenting ICU hospitalizations were retrieved from the MIMIC-IV database. From this dataset, 53,150 patient records pertaining to the initial ICU admission were meticulously selected. Following the exclusion of patients due to age or incomplete data, a final cohort of 50,624 individuals was formed, comprising 15,630 statin users and 34,994 nonusers. PSM analysis was executed, as illustrated in <xref rid="f1" ref-type="fig"><italic toggle="yes">Figure 1</italic></xref>.</p><fig position="float" id="f1" fig-type="figure" orientation="portrait"><label>Figure 1</label><caption><p>The flowchart of the cohort selection process. ICU, intensive care unit; MIMIC-IV, Medical Information Mart for Intensive Care IV.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="jtd-17-01-429-f1.jpg"/></fig></sec><sec><title>Baseline characteristics</title><p>Comparative analysis of baseline characteristics revealed that individuals in the statin group exhibited an advanced age and a higher proportion of males compared to their non-statin-treated counterparts (62.0%<italic toggle="yes"> vs. </italic>53.1%); the statin group also had a higher percentage of Medicare recipients (50.2%<italic toggle="yes"> vs. </italic>39.5%) and elevated rates of concurrent aspirin usage (70.8%<italic toggle="yes"> vs. </italic>18.2%). In terms of comorbidities, the statin group had higher incidences of congestive heart failure (CHF), AKI, myocardial infarction, and COPD. Notably, the prevalence of severe liver disease was lower in the statin group than in the nonstatin (0.9%<italic toggle="yes"> vs. </italic>5.9%), underscoring hepatotoxicity as a principal adverse effect of statins (see <xref rid="t1" ref-type="table"><italic toggle="yes">Table 1</italic></xref>). After PSM, a significant reduction in SMDs between the two groups was observed. Prior to PSM adjustment, most covariates exhibited imbalances between the statin group and nonstatin group; after PSM, the SMD for all covariates was &lt;0.10, indicative of balanced inclusion of covariates between the two groups (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://cdn.amegroups.cn/static/public/JTD-2024-2243-Supplementary.pdf" ext-link-type="uri">Figure S1</ext-link>).</p><table-wrap position="float" id="t1" orientation="portrait"><label>Table 1</label><caption><title>Comparison of characteristics between statin users and nonusers before and after PSM</title></caption><table frame="hsides" rules="groups"><col width="19.33%" span="1"/><col width="16.33%" span="1"/><col width="15.15%" span="1"/><col width="9.43%" span="1"/><col width="0.48%" span="1"/><col width="15.1%" span="1"/><col width="15.1%" span="1"/><col width="9.08%" span="1"/><thead><tr><th rowspan="2" valign="middle" align="left" scope="col" style="border-bottom: solid 0.50pt" colspan="1">Characteristics</th><th valign="middle" colspan="3" align="center" scope="colgroup" style="border-bottom: solid 0.50pt" rowspan="1">Unmatched patients</th><th rowspan="2" valign="middle" align="left" scope="col" style="border-bottom: solid 0.50pt" colspan="1"/><th valign="middle" colspan="3" align="center" scope="colgroup" style="border-bottom: solid 0.50pt" rowspan="1">Propensity score-matched patients</th></tr><tr><th valign="middle" colspan="1" align="center" scope="colgroup" style="border-top: solid 0.50pt" rowspan="1">No statins (n=34,994)</th><th valign="middle" align="center" scope="col" style="border-top: solid 0.50pt" rowspan="1" colspan="1">Statins (n=15,630)</th><th valign="middle" align="center" scope="col" style="border-top: solid 0.50pt" rowspan="1" colspan="1">SMD</th><th valign="middle" colspan="1" align="center" scope="colgroup" style="border-top: solid 0.50pt" rowspan="1">No statins (n=10,646)</th><th valign="middle" align="center" scope="col" style="border-top: solid 0.50pt" rowspan="1" colspan="1">Statins (n=10,646)</th><th valign="middle" align="center" scope="col" style="border-top: solid 0.50pt" rowspan="1" colspan="1">SMD</th></tr></thead><tbody><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Age (years)</td><td valign="top" align="center" rowspan="1" colspan="1">62.2&#177;18.5</td><td valign="top" align="center" rowspan="1" colspan="1">71.1&#177;12.2</td><td valign="top" align="center" rowspan="1" colspan="1">0.57</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">70.9&#177;14.5</td><td valign="top" align="center" rowspan="1" colspan="1">69.9&#177;12.7</td><td valign="top" align="center" rowspan="1" colspan="1">0.075</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Male</td><td valign="top" align="center" rowspan="1" colspan="1">18,576 (53.1)</td><td valign="top" align="center" rowspan="1" colspan="1">9,694 (62.0)</td><td valign="top" align="center" rowspan="1" colspan="1">0.182</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">6,091 (57.2)</td><td valign="top" align="center" rowspan="1" colspan="1">6,224 (58.5)</td><td valign="top" align="center" rowspan="1" colspan="1">0.025</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Race</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">0.108</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">0.011</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">&#160;&#160;&#160;White</td><td valign="top" align="center" rowspan="1" colspan="1">23,342 (66.7)</td><td valign="top" align="center" rowspan="1" colspan="1">10,817 (69.2)</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">7,372 (69.2)</td><td valign="top" align="center" rowspan="1" colspan="1">7,327 (68.8)</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">&#160;&#160;&#160;Asian</td><td valign="top" align="center" rowspan="1" colspan="1">1,109 (3.2)</td><td valign="top" align="center" rowspan="1" colspan="1">383 (2.5)</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">281 (2.6)</td><td valign="top" align="center" rowspan="1" colspan="1">289 (2.7)</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">&#160;&#160;&#160;Black</td><td valign="top" align="center" rowspan="1" colspan="1">3,480 (9.9)</td><td valign="top" align="center" rowspan="1" colspan="1">1,133 (7.2)</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">905 (8.5)</td><td valign="top" align="center" rowspan="1" colspan="1">901 (8.5)</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">&#160;&#160;&#160;Other</td><td valign="top" align="center" rowspan="1" colspan="1">7,063 (20.2)</td><td valign="top" align="center" rowspan="1" colspan="1">3,297 (21.1)</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">2,088 (19.6)</td><td valign="top" align="center" rowspan="1" colspan="1">2,129 (20.0)</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Aspirin</td><td valign="top" align="center" rowspan="1" colspan="1">6,373 (18.2)</td><td valign="top" align="center" rowspan="1" colspan="1">11,073 (70.8)</td><td valign="top" align="center" rowspan="1" colspan="1">1.248</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">5,900 (55.4)</td><td valign="top" align="center" rowspan="1" colspan="1">6,090 (57.2)</td><td valign="top" align="center" rowspan="1" colspan="1">0.036</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Insurance</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">0.262</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">0.039</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">&#160;&#160;&#160;Medicaid</td><td valign="top" align="center" rowspan="1" colspan="1">3,003 (8.6)</td><td valign="top" align="center" rowspan="1" colspan="1">612 (3.9)</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">426 (4.0)</td><td valign="top" align="center" rowspan="1" colspan="1">479 (4.5)</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">&#160;&#160;&#160;Medicare</td><td valign="top" align="center" rowspan="1" colspan="1">13,835 (39.5)</td><td valign="top" align="center" rowspan="1" colspan="1">7,842 (50.2)</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">5,412 (50.8)</td><td valign="top" align="center" rowspan="1" colspan="1">5,228 (49.1)</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">&#160;&#160;&#160;Other</td><td valign="top" align="center" rowspan="1" colspan="1">18,156 (51.9)</td><td valign="top" align="center" rowspan="1" colspan="1">7,176 (45.9)</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">4,808 (45.2)</td><td valign="top" align="center" rowspan="1" colspan="1">4,939 (46.4)</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">APSIII score</td><td valign="top" align="center" rowspan="1" colspan="1">46.14&#177;24.05</td><td valign="top" align="center" rowspan="1" colspan="1">41.53&#177;19.64</td><td valign="top" align="center" rowspan="1" colspan="1">0.21</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">42.86&#177;19.80</td><td valign="top" align="center" rowspan="1" colspan="1">43.07&#177;20.70</td><td valign="top" align="center" rowspan="1" colspan="1">0.01</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">CCI score</td><td valign="top" align="center" rowspan="1" colspan="1">5.05&#177;3.13</td><td valign="top" align="center" rowspan="1" colspan="1">6.04&#177;2.51</td><td valign="top" align="center" rowspan="1" colspan="1">0.351</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">5.99&#177;2.77</td><td valign="top" align="center" rowspan="1" colspan="1">5.89&#177;2.57</td><td valign="top" align="center" rowspan="1" colspan="1">0.036</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">CHF</td><td valign="top" align="center" rowspan="1" colspan="1">6,911 (19.7)</td><td valign="top" align="center" rowspan="1" colspan="1">4,978 (31.8)</td><td valign="top" align="center" rowspan="1" colspan="1">0.279</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">3,243 (30.5)</td><td valign="top" align="center" rowspan="1" colspan="1">3,149 (29.6)</td><td valign="top" align="center" rowspan="1" colspan="1">0.019</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Renal disease</td><td valign="top" align="center" rowspan="1" colspan="1">5,359 (15.3)</td><td valign="top" align="center" rowspan="1" colspan="1">3,489 (22.3)</td><td valign="top" align="center" rowspan="1" colspan="1">0.18</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">2,294 (21.5)</td><td valign="top" align="center" rowspan="1" colspan="1">2,260 (21.2)</td><td valign="top" align="center" rowspan="1" colspan="1">0.008</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Severe liver disease</td><td valign="top" align="center" rowspan="1" colspan="1">2,055 (5.9)</td><td valign="top" align="center" rowspan="1" colspan="1">144 (0.9)</td><td valign="top" align="center" rowspan="1" colspan="1">0.276</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">108 (1.0)</td><td valign="top" align="center" rowspan="1" colspan="1">142 (1.3)</td><td valign="top" align="center" rowspan="1" colspan="1">0.03</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Sepsis</td><td valign="top" align="center" rowspan="1" colspan="1">15,725 (44.9)</td><td valign="top" align="center" rowspan="1" colspan="1">6,802 (43.5)</td><td valign="top" align="center" rowspan="1" colspan="1">0.029</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">4,707 (44.2)</td><td valign="top" align="center" rowspan="1" colspan="1">4,718 (44.3)</td><td valign="top" align="center" rowspan="1" colspan="1">0.002</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">AKI</td><td valign="top" align="center" rowspan="1" colspan="1">18,432 (52.7)</td><td valign="top" align="center" rowspan="1" colspan="1">9,341 (59.8)</td><td valign="top" align="center" rowspan="1" colspan="1">0.143</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">6,154 (57.8)</td><td valign="top" align="center" rowspan="1" colspan="1">6,112 (57.4)</td><td valign="top" align="center" rowspan="1" colspan="1">0.008</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">MI</td><td valign="top" align="center" rowspan="1" colspan="1">3,265 (9.3)</td><td valign="top" align="center" rowspan="1" colspan="1">4,788 (30.6)</td><td valign="top" align="center" rowspan="1" colspan="1">0.553</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">2,123 (19.9)</td><td valign="top" align="center" rowspan="1" colspan="1">2,286 (21.5)</td><td valign="top" align="center" rowspan="1" colspan="1">0.038</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">COPD</td><td valign="top" align="center" rowspan="1" colspan="1">7,974 (22.8)</td><td valign="top" align="center" rowspan="1" colspan="1">3,816 (24.4)</td><td valign="top" align="center" rowspan="1" colspan="1">0.038</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">2,711 (25.5)</td><td valign="top" align="center" rowspan="1" colspan="1">2,634 (24.7)</td><td valign="top" align="center" rowspan="1" colspan="1">0.017</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Heart rate (bpm)</td><td valign="top" align="center" rowspan="1" colspan="1">85.7&#177;16.4</td><td valign="top" align="center" rowspan="1" colspan="1">81.0&#177;13.4</td><td valign="top" align="center" rowspan="1" colspan="1">0.313</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">81.5&#177;14.7</td><td valign="top" align="center" rowspan="1" colspan="1">81.9&#177;13.9</td><td valign="top" align="center" rowspan="1" colspan="1">0.022</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">SBP (mmHg)</td><td valign="top" align="center" rowspan="1" colspan="1">119.1&#177;16.7</td><td valign="top" align="center" rowspan="1" colspan="1">119.1&#177;15.7</td><td valign="top" align="center" rowspan="1" colspan="1">0.002</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">120.0&#177;16.5</td><td valign="top" align="center" rowspan="1" colspan="1">119.7&#177;16.2</td><td valign="top" align="center" rowspan="1" colspan="1">0.016</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">DBP (mmHg)</td><td valign="top" align="center" rowspan="1" colspan="1">64.7&#177;11.4</td><td valign="top" align="center" rowspan="1" colspan="1">62.1&#177;10.9</td><td valign="top" align="center" rowspan="1" colspan="1">0.241</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">62.8&#177;11.1</td><td valign="top" align="center" rowspan="1" colspan="1">62.9&#177;11.1</td><td valign="top" align="center" rowspan="1" colspan="1">0.003</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">RR </td><td valign="top" align="center" rowspan="1" colspan="1">19.2&#177;3.9</td><td valign="top" align="center" rowspan="1" colspan="1">18.6&#177;3.2</td><td valign="top" align="center" rowspan="1" colspan="1">0.149</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">18.7&#177;3.5</td><td valign="top" align="center" rowspan="1" colspan="1">18.8&#177;3.3</td><td valign="top" align="center" rowspan="1" colspan="1">0.007</td></tr></tbody></table><table-wrap-foot><p>Data are presented as mean &#177; standard or n (%). PSM, propensity score matching; SMD, standard mean deviation; APSIII, Acute Physiology Score III; CCI, Charlson comorbidity index; CHF, congestive heart failure; AKI, acute kidney injury; MI, myocardial infarction; COPD, chronic obstructive pulmonary disease; SBP, systolic blood pressure; DBP, diastolic blood pressure; RR, respiratory rate.</p></table-wrap-foot></table-wrap></sec><sec><title>Univariate analysis</title><p>Following PSM, univariate analysis was conducted on patients to clarify the association between covariates and 28-day mortality in the ICU. The statin group exhibited lower mortality compared to the nonstatin group, with reductions of 29% for atorvastatin, 48% for rosuvastatin, 44% for simvastatin, and 28% for other statins. Patients aged 65 years or older had a mortality rate 2.06 times higher than their counterparts younger than 65 years. Individuals using aspirin demonstrated a 31% lower risk of death compared to those not using aspirin. Additionally, an increase in mortality of 4% per 1-point increase in Acute Physiology Score III (APSIII) score, a 25% increase per 1-point rise in the Charlson comorbidity index (CCI) score, and elevated mortality in patients with comorbidities compared to those without comorbidities were observed (<xref rid="t2" ref-type="table"><italic toggle="yes">Table 2</italic></xref>).</p><table-wrap position="float" id="t2" orientation="portrait"><label>Table 2</label><caption><title>Univariable analysis of status in the PSM cohort</title></caption><table frame="hsides" rules="groups"><col width="44.6%" span="1"/><col width="35.75%" span="1"/><col width="19.65%" span="1"/><thead><tr><th valign="middle" align="left" scope="col" rowspan="1" colspan="1">Item</th><th valign="middle" align="center" scope="col" rowspan="1" colspan="1">HR (95% CI)</th><th valign="middle" align="center" scope="col" rowspan="1" colspan="1">P</th></tr></thead><tbody><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">Statins</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">&#160;&#160;&#160;No statins</td><td valign="top" align="center" rowspan="1" colspan="1">Reference</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">&#160;&#160;&#160;Atorvastatin</td><td valign="top" align="center" rowspan="1" colspan="1">0.71 (0.64, 0.78)</td><td valign="top" align="center" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">&#160;&#160;&#160;Rosuvastatin</td><td valign="top" align="center" rowspan="1" colspan="1">0.52 (0.4, 0.7)</td><td valign="top" align="center" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">&#160;&#160;&#160;Simvastatin</td><td valign="top" align="center" rowspan="1" colspan="1">0.56 (0.48, 0.64)</td><td valign="top" align="center" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">&#160;&#160;&#160;Other</td><td valign="top" align="center" rowspan="1" colspan="1">0.72 (0.58, 0.9)</td><td valign="top" align="center" rowspan="1" colspan="1">0.004</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Age (&#8805;65 <italic toggle="yes">vs</italic>. &lt;65 years)</td><td valign="top" align="center" rowspan="1" colspan="1">3.06 (2.71, 3.44)</td><td valign="top" align="center" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Gender (male <italic toggle="yes">vs</italic>. female)</td><td valign="top" align="center" rowspan="1" colspan="1">0.86 (0.79, 0.93)</td><td valign="top" align="center" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">Race</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">&#160;&#160;&#160;White</td><td valign="top" align="center" rowspan="1" colspan="1">Reference</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">&#160;&#160;&#160;Asian</td><td valign="top" align="center" rowspan="1" colspan="1">0.9 (0.68, 1.19)</td><td valign="top" align="center" rowspan="1" colspan="1">0.46</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">&#160;&#160;&#160;Black</td><td valign="top" align="center" rowspan="1" colspan="1">0.88 (0.75, 1.04)</td><td valign="top" align="center" rowspan="1" colspan="1">0.13</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">&#160;&#160;&#160;Other</td><td valign="top" align="center" rowspan="1" colspan="1">1.52 (1.38, 1.67)</td><td valign="top" align="center" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Aspirin (yes <italic toggle="yes">vs</italic>. no)</td><td valign="top" align="center" rowspan="1" colspan="1">0.69 (0.64, 0.75)</td><td valign="top" align="center" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">Insurance</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">&#160;&#160;&#160;Medicaid</td><td valign="top" align="center" rowspan="1" colspan="1">Reference</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">&#160;&#160;&#160;Medicare</td><td valign="top" align="center" rowspan="1" colspan="1">2.1 (1.62, 2.72)</td><td valign="top" align="center" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">&#160;&#160;&#160;Other</td><td valign="top" align="center" rowspan="1" colspan="1">1.24 (0.95, 1.62)</td><td valign="top" align="center" rowspan="1" colspan="1">0.11</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">APSIII</td><td valign="top" align="center" rowspan="1" colspan="1">1.04 (1.04, 1.04)</td><td valign="top" align="center" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">CCI</td><td valign="top" align="center" rowspan="1" colspan="1">1.25 (1.24, 1.27)</td><td valign="top" align="center" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">CHF (yes <italic toggle="yes">vs</italic>. no)</td><td valign="top" align="center" rowspan="1" colspan="1">1.83 (1.68, 1.99)</td><td valign="top" align="center" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Renal disease (yes <italic toggle="yes">vs</italic>. no)</td><td valign="top" align="center" rowspan="1" colspan="1">1.76 (1.61, 1.93)</td><td valign="top" align="center" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Severe liver disease (yes <italic toggle="yes">vs</italic>. no)</td><td valign="top" align="center" rowspan="1" colspan="1">2.7 (2.11, 3.45)</td><td valign="top" align="center" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Sepsis (yes <italic toggle="yes">vs</italic>. no)</td><td valign="top" align="center" rowspan="1" colspan="1">2.11 (1.94, 2.3)</td><td valign="top" align="center" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">AKI (yes <italic toggle="yes">vs</italic>. no)</td><td valign="top" align="center" rowspan="1" colspan="1">2.38 (2.16, 2.63)</td><td valign="top" align="center" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">MI (yes <italic toggle="yes">vs</italic>. no)</td><td valign="top" align="center" rowspan="1" colspan="1">1.84 (1.68, 2.01)</td><td valign="top" align="center" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">COPD (yes <italic toggle="yes">vs</italic>. no)</td><td valign="top" align="center" rowspan="1" colspan="1">1.22 (1.11, 1.34)</td><td valign="top" align="center" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Heart rate</td><td valign="top" align="center" rowspan="1" colspan="1">1.02 (1.02, 1.02)</td><td valign="top" align="center" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">SBP</td><td valign="top" align="center" rowspan="1" colspan="1">0.99 (0.98, 0.99)</td><td valign="top" align="center" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">DBP</td><td valign="top" align="center" rowspan="1" colspan="1">0.98 (0.98, 0.99)</td><td valign="top" align="center" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">RR</td><td valign="top" align="center" rowspan="1" colspan="1">1.15 (1.14, 1.16)</td><td valign="top" align="center" rowspan="1" colspan="1">&lt;0.001</td></tr></tbody></table><table-wrap-foot><p>PSM, propensity score matching; HR, hazard ratio; CI, confidence interval; APSIII, Acute Physiology Score III; CCI, Charlson comorbidity index; CHF, congestive heart failure; AKI, acute kidney injury; MI, myocardial infarction; COPD, chronic obstructive pulmonary disease; SBP, systolic blood pressure; DBP, diastolic blood pressure; RR, respiratory rate.</p></table-wrap-foot></table-wrap></sec><sec><title>Multivariate analysis</title><p>After PSM, 6,213 (58.36%) in the atorvastatin group, 730 (6.86%) in the rosuvastatin group, 2,817 (26.46%) in the simvastatin group, and 886 (8.32%) in the other statin group. After PSM and adjustment for all covariates to mitigate confounding effects, patients in the statin group exhibited an overall 31% lower risk of death compared to the nonstatin group [hazard ratio (HR) =0.69; 95% confidence interval (CI): 0.63&#8211;0.75; P&lt;0.001]. As it relates to different statin types, compared to the nonstatin group, atorvastatin demonstrated a 26% lower risk (HR =0.74; 95% CI: 0.67&#8211;0.82; P&lt;0.001), rosuvastatin a 34% lower risk (HR =0.66; 95% CI: 0.5&#8211;0.88; P=0.004), simvastatin a 44% lower risk (HR =0.56; 95% CI: 0.48&#8211;0.65; P&lt;0.001), and other statins a 26% lower risk (HR =0.74; 95% CI: 0.59&#8211;0.92; P=0.008) (<xref rid="t3" ref-type="table"><italic toggle="yes">Table 3</italic></xref>). Please refer to <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://cdn.amegroups.cn/static/public/JTD-2024-2243-Supplementary.pdf" ext-link-type="uri">Table S1</ext-link> for the pre-PSM results.</p><table-wrap position="float" id="t3" orientation="portrait"><label>Table 3</label><caption><title>Multivariable analysis for statin use in the propensity score-matched cohort (n=21,292)</title></caption><table frame="hsides" rules="groups"><col width="24.23%" span="1"/><col width="14.42%" span="1"/><col width="23.33%" span="1"/><col width="21.57%" span="1"/><col width="16.45%" span="1"/><thead><tr><th valign="middle" align="left" scope="col" rowspan="1" colspan="1">Variables</th><th valign="middle" align="center" scope="col" rowspan="1" colspan="1">Total, n</th><th valign="middle" align="center" scope="col" rowspan="1" colspan="1">28-day mortality, n (%)</th><th valign="middle" align="center" scope="col" rowspan="1" colspan="1">Adj. HR (95% CI)</th><th valign="middle" align="center" scope="col" rowspan="1" colspan="1">Adj. P value</th></tr></thead><tbody><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">Model 1: statin use</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">&#160;&#160;&#160;No statins</td><td valign="top" align="center" rowspan="1" colspan="1">10,646</td><td valign="top" align="center" rowspan="1" colspan="1">1,339 (12.6)</td><td valign="top" align="center" rowspan="1" colspan="1">1 (reference)</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">&#160;&#160;&#160;Statins</td><td valign="top" align="center" rowspan="1" colspan="1">10,646</td><td valign="top" align="center" rowspan="1" colspan="1">904 (8.5)</td><td valign="top" align="center" rowspan="1" colspan="1">0.69 (0.63&#8211;0.75)</td><td valign="top" align="center" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">Model 2: type of statin</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">&#160;&#160;&#160;No statins</td><td valign="top" align="center" rowspan="1" colspan="1">10,646</td><td valign="top" align="center" rowspan="1" colspan="1">1,339 (12.6)</td><td valign="top" align="center" rowspan="1" colspan="1">1 (reference)</td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">&#160;&#160;&#160;Atorvastatin</td><td valign="top" align="center" rowspan="1" colspan="1">6,213</td><td valign="top" align="center" rowspan="1" colspan="1">568 (9.1)</td><td valign="top" align="center" rowspan="1" colspan="1">0.74 (0.67&#8211;0.82)</td><td valign="top" align="center" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">&#160;&#160;&#160;Rosuvastatin</td><td valign="top" align="center" rowspan="1" colspan="1">730</td><td valign="top" align="center" rowspan="1" colspan="1">50 (6.8)</td><td valign="top" align="center" rowspan="1" colspan="1">0.66 (0.5&#8211;0.88)</td><td valign="top" align="center" rowspan="1" colspan="1">0.004</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">&#160;&#160;&#160;Simvastatin</td><td valign="top" align="center" rowspan="1" colspan="1">2,817</td><td valign="top" align="center" rowspan="1" colspan="1">204 (7.2)</td><td valign="top" align="center" rowspan="1" colspan="1">0.56 (0.48&#8211;0.65)</td><td valign="top" align="center" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">&#160;&#160;&#160;Other statins</td><td valign="top" align="center" rowspan="1" colspan="1">886</td><td valign="top" align="center" rowspan="1" colspan="1">82 (9.3)</td><td valign="top" align="center" rowspan="1" colspan="1">0.74 (0.59&#8211;0.92)</td><td valign="top" align="center" rowspan="1" colspan="1">0.008</td></tr></tbody></table><table-wrap-foot><p>Adj., adjusted; HR, hazard ratio; CI, confidence interval.</p></table-wrap-foot></table-wrap></sec><sec><title>Survival analysis</title><p>The Kaplan-Meier survival curves indicated that the 28-day survival probability of the statin group surpassed that of the nonstatin group. Before PSM, the cohort comprised 50,624 patients, with 15,630 in the statin group and 34,994 in the nonstatin group, and the respective survival probabilities were 92.09% and 85.05%. Stratification by specific statins indicated survival rates of 94.08% for rosuvastatin, 93.32% for simvastatin, 91.66% for other statins, and 91.43% for atorvastatin. Following PSM, a total of 21,292 patients were included, who were evenly distributed between the statin and nonstatin groups (10,646 each). The corresponding survival probabilities were 91.51% and 87.42%. Stratified analysis based on individual statins indicated survival rates of 93.15% for rosuvastatin, 92.76% for simvastatin, 90.74% for other statins, and 90.86% for atorvastatin (<xref rid="f2" ref-type="fig"><italic toggle="yes">Figure 2</italic></xref>).</p><fig position="float" id="f2" fig-type="figure" orientation="portrait"><label>Figure 2</label><caption><p>Kaplan-Meier survival curves for patients with and without statin administration. PSM, propensity score matching.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="jtd-17-01-429-f2.jpg"/></fig></sec><sec><title>Subgroup analysis</title><p>Within the various subgroups, including patients diagnosed with COPD, AKI, sepsis, and myocardial infarction, the use of statins exhibited an association with a diminished 28-day mortality rate. Conversely, in the context of severe liver disease, statin use did not demonstrate a reduction in 28-day mortality and may notably pose a risk factor for mortality in patients with severe liver disease. There was no difference between the sexes regarding the association between statin use and 28-day mortality (P&gt;0.05) (<xref rid="f3" ref-type="fig"><italic toggle="yes">Figure 3</italic></xref>).</p><fig position="float" id="f3" fig-type="figure" orientation="portrait"><label>Figure 3</label><caption><p>Subgroup analysis of statin use and 28-day mortality. HR, hazard ratio; CI, confidence interval; Ref, reference; CHF, congestive heart failure; AKI, acute kidney injury; MI, myocardial infarction; COPD, chronic obstructive pulmonary disease.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="jtd-17-01-429-f3.jpg"/></fig></sec><sec><title>Sensitivity analysis</title><p>We generate a PSM among the statin and non-statin group using a multivariable regression model. A 1:1 nearest neighbor matching algorithm was applied using a caliper width of 0.01. An SMD was used to examine the PSM degree. Furthermore, the variables mentioned above as covariates were selected to generate the propensity score. The estimated propensity scores were used as weights. Pairwise algorithmic (PA), standardized mortality ratio weight (SMRW) models were used to generate a weighted cohort to adjust the baseline confounders, thus reflecting more truly the independent association between statin use and mortality.</p><p>The E value (<xref rid="r21" ref-type="bibr">21</xref>) of this study was 2.26, signifying that in the presence of an unmeasured covariate, the association with 28-day mortality was required to surpass a threshold of at least 2.26 to exert an impact on the robustness of the findings.</p></sec></sec><sec sec-type="discussion"><title>Discussion</title><sec><title>Statement of key findings</title><p>Using the MIMC-IV database, we sought to clarify the potential link between statin usage and 28-day mortality among patients in the ICU. The comprehensive retrospective cohort analysis revealed a significant association between statin therapy and a reduced risk of 28-day all-cause mortality in patients in the ICU. The robustness of these results persisted even after PSM, multivariate analysis, and subgroup analyses. Notably, the observed association was most pronounced in the simvastatin group.</p></sec><sec sec-type="discussion"><title>Interpretation</title><p>Studies have presented conflicting findings regarding the impact of statins on mortality in critically ill patients. Christensen<italic toggle="yes"> et al. </italic>(<xref rid="r22" ref-type="bibr">22</xref>) conducted a retrospective analysis involving over 10,000 critically ill patients and found that preadmission statin use was associated with a reduced risk of death after intensive care. Similarly, Kyu Oh<italic toggle="yes"> et al. </italic>(<xref rid="r23" ref-type="bibr">23</xref>) examined more than 20,000 critically ill adults, revealing that preadmission statin use, particularly with rosuvastatin, was linked to lower 90-day mortality, even in cases without cardiovascular disease. The study conducted by Yao<italic toggle="yes"> et al. </italic>used the MIMIC-IV database to examine the correlation between statin usage and the risk of in-hospital mortality among patients with sepsis-induced coagulation disorder. The findings suggested a significant association between statin administration and a decreased likelihood of in-hospital death in individuals with sepsis-induced coagulopathy (SIC) (<xref rid="r24" ref-type="bibr">24</xref>). The administration of statins prior to admission in patients with acute respiratory distress syndrome (ARDS) has been associated with potential clinical benefits. For instance, pre-ICU administration of statins was found to produce a significant reduction in both 30- and 90-day mortality rates, as well as a decrease in ICU length of stay among patients with ARDS; these findings support the efficacy of statin therapy for the treatment of ARDS (<xref rid="r25" ref-type="bibr">25</xref>). Recent cell culture experiments have found that simvastatin can inhibit the growth of pancreatic neuroendocrine tumors both<italic toggle="yes"> in vivo </italic>and<italic toggle="yes"> in vitro</italic>. These findings highlight simvastatin as a promising candidate drug for the treatment of neuroendocrine tumors (<xref rid="r26" ref-type="bibr">26</xref>). Wang<italic toggle="yes"> et al. </italic>provided evidence for the potential protective effect of simvastatin against gastric cancer through Mendelian randomization studies. Considering the use of simvastatin as an adjuvant to traditional cancer treatments may propose a new strategy to improve patient outcomes (<xref rid="r27" ref-type="bibr">27</xref>). In contrast, Papazian<italic toggle="yes"> et al. </italic>(<xref rid="r28" ref-type="bibr">28</xref>) completed a multicenter randomized controlled trial (RCT) in 26 French ICUs and reported that adjunctive simvastatin therapy did not enhance 28-day survival in adults with suspected ventilator-associated pneumonia (VAP). The authors speculated that this discrepancy could be due to variations in statin toxicity and renal elimination between critically ill patients and healthy individuals and emphasized the notably high peak plasma statin levels in the former. Our study diverges from previous meta-analyses that reported no mortality benefit from statin therapy in patients with sepsis or acute lung injury/ARDS (<xref rid="r29" ref-type="bibr">29</xref>,<xref rid="r30" ref-type="bibr">30</xref>). Notably, we focused on a diverse ICU population using a large public database, including patients admitted with at least 3 days of statin use irrespective of their preadmission statin history. This approach allowed us to investigate the potential pleiotropic effect of statins on all-cause mortality. It is important to note that previous randomized clinical trials often targeted specific conditions such as acute lung injury/ARDS, VAP, or sepsis. Mixed ICU populations, as in our study, may generally have healthier individuals or encounter more self-limiting diseases. This divergence in patient characteristics could explain the differences in outcomes between our study and previous research.</p></sec><sec><title>Strengths and weaknesses</title><p>Our study involved several limitations that warrant further consideration. First, we employed a retrospective, observational design using pre-existing data and did not conduct randomization. Second, due to an incomplete long-term follow-up in the database, a comprehensive long-term effect analysis was not feasible, and thus our focus was on 28-day mortality. Third, there were limitations related to the population selection, specifically for previously healthy patients admitted to the hospital for accidental injury. In cases where there were no comorbidities, such as infection during hospitalization, and no indications for statin use, the mortality rate of patients in the nonstatin group might have been inflated solely due to trauma-related deaths, introducing bias into the results. Nevertheless, we implemented rigorous methods to address both known and unknown confounding factors. Techniques such as PSM, multifactor analysis, and calculation of the E value were employed, yielding relatively robust research outcomes. The results of our subgroup analysis point to the potential benefits of statin use in clinical practice for patients with sepsis, AKI, myocardial infarction, or COPD. This information can serve as a valuable reference for clinicians in optimizing treatment strategies.</p></sec><sec><title>Further research</title><p>Future large-scale, multicenter, RCTs are needed to verify the potential pleiotropic effects of statins.</p></sec></sec><sec sec-type="conclusions"><title>Conclusions</title><p>Statin use was potentially associated with a reduction in the 28-day all-cause mortality among patients in the ICU, and this association was more pronounced in the simvastatin group.</p></sec><sec sec-type="supplementary-material"><title>Supplementary</title><supplementary-material position="float" content-type="local-data" orientation="portrait"><p>The article&#8217;s supplementary files as</p></supplementary-material><supplementary-material position="anchor" id="su1" content-type="local-data" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jtd-17-01-429-rc.pdf" id="d67e1257" position="anchor" orientation="portrait"><object-id pub-id-type="doi">10.21037/jtd-2024-2243</object-id></media><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jtd-17-01-429-coif.pdf" id="d67e1260" position="anchor" orientation="portrait"><object-id pub-id-type="doi">10.21037/jtd-2024-2243</object-id></media><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jtd-17-01-429-supplementary.pdf" id="d67e1263" position="anchor" orientation="portrait"><object-id pub-id-type="doi">10.21037/jtd-2024-2243</object-id></media></supplementary-material></sec></body><back><ack><title>Acknowledgments</title><p>We would like to thank the staff of the Department of Pharmacy, The Second Hospital of Hebei Medical University, for their guidance and help. We would also like to express our gratitude to the team of clinical scientists for their helpful review and comments regarding the manuscript.</p></ack><fn-group><fn id="fn1"><p><italic toggle="yes">Reporting Checklist:</italic> The authors have completed the STROBE reporting checklist. Available at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://jtd.amegroups.com/article/view/10.21037/jtd-2024-2243/rc" ext-link-type="uri">https://jtd.amegroups.com/article/view/10.21037/jtd-2024-2243/rc</ext-link></p></fn><fn fn-type="financial-disclosure"><p><italic toggle="yes">Funding:</italic> None.</p></fn><fn fn-type="COI-statement"><p><italic toggle="yes">Conflicts of Interest:</italic> All authors have completed the ICMJE uniform disclosure form (available at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://jtd.amegroups.com/article/view/10.21037/jtd-2024-2243/coif" ext-link-type="uri">https://jtd.amegroups.com/article/view/10.21037/jtd-2024-2243/coif</ext-link>). The authors have no conflicts of interest to declare.</p></fn></fn-group><fn-group><fn id="fn3"><p>(English Language Editor: J. Gray)</p></fn></fn-group><notes><p content-type="note added in proof"><italic toggle="yes">Ethical Statement:</italic> The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. The study was conducted in accordance with the Declaration of Helsinki (as revised in 2013).</p></notes><ref-list><title>References</title><ref id="r1"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kulkarni</surname><given-names>S</given-names></name><name name-style="western"><surname>Watts</surname><given-names>MM</given-names></name><name name-style="western"><surname>Kostapanos</surname><given-names>M</given-names></name></person-group>. <article-title>Statins.</article-title><source>BMJ</source><year>2024</year>;<volume>384</volume>:<elocation-id>e072584</elocation-id>. <pub-id pub-id-type="doi">10.1136/bmj-2022-072584</pub-id><pub-id pub-id-type="pmid">38267068</pub-id></mixed-citation></ref><ref id="r2"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><collab>Joint Committee on the Chinese Guidelines for Lipid Management</collab></person-group>. <article-title>Chinese guidelines for lipid management (2023).</article-title><source>Zhonghua Xin Xue Guan Bing Za Zhi</source><year>2023</year>;<volume>51</volume>:<fpage>221</fpage>-<lpage>55</lpage>. <pub-id pub-id-type="doi">10.3760/cma.j.cn112148-20230119-00038</pub-id><pub-id pub-id-type="pmid">36925135</pub-id></mixed-citation></ref><ref id="r3"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mach</surname><given-names>F.</given-names></name></person-group><article-title>Statins as immunomodulatory agents.</article-title><source>Circulation</source><year>2004</year>;<volume>109</volume>:<fpage>II15</fpage>-<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1161/01.CIR.0000129502.10459.fe</pub-id><pub-id pub-id-type="pmid">15173058</pub-id></mixed-citation></ref><ref id="r4"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Viasus</surname><given-names>D</given-names></name><name name-style="western"><surname>Garcia-Vidal</surname><given-names>C</given-names></name><name name-style="western"><surname>Simonetti</surname><given-names>AF</given-names></name><etal/></person-group><article-title>The effect of simvastatin on inflammatory cytokines in community-acquired pneumonia: a randomised, double-blind, placebo-controlled trial.</article-title><source>BMJ Open</source><year>2015</year>;<volume>5</volume>:<elocation-id>e006251</elocation-id>. <pub-id pub-id-type="doi">10.1136/bmjopen-2014-006251</pub-id><pub-id pub-id-type="pmid">25564143</pub-id><pub-id pub-id-type="pmcid">PMC4289727</pub-id></mixed-citation></ref><ref id="r5"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Glynn</surname><given-names>RJ</given-names></name><name name-style="western"><surname>Danielson</surname><given-names>E</given-names></name><name name-style="western"><surname>Fonseca</surname><given-names>FA</given-names></name><etal/></person-group><article-title>A randomized trial of rosuvastatin in the prevention of venous thromboembolism.</article-title><source>N Engl J Med</source><year>2009</year>;<volume>360</volume>:<fpage>1851</fpage>-<lpage>61</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMoa0900241</pub-id><pub-id pub-id-type="pmid">19329822</pub-id><pub-id pub-id-type="pmcid">PMC2710995</pub-id></mixed-citation></ref><ref id="r6"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mihos</surname><given-names>CG</given-names></name><name name-style="western"><surname>Salas</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Santana</surname><given-names>O</given-names></name></person-group>. <article-title>The pleiotropic effects of the hydroxy-methyl-glutaryl-CoA reductase inhibitors in cardiovascular disease: a comprehensive review.</article-title><source>Cardiol Rev</source><year>2010</year>;<volume>18</volume>:<fpage>298</fpage>-<lpage>304</lpage>. <pub-id pub-id-type="doi">10.1097/CRD.0b013e3181f52a7f</pub-id><pub-id pub-id-type="pmid">20926939</pub-id></mixed-citation></ref><ref id="r7"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>He</surname><given-names>Y</given-names></name><name name-style="western"><surname>Li</surname><given-names>X</given-names></name><name name-style="western"><surname>Gasevic</surname><given-names>D</given-names></name><etal/></person-group><article-title>Statins and Multiple Noncardiovascular Outcomes: Umbrella Review of Meta-analyses of Observational Studies and Randomized Controlled Trials.</article-title><source>Ann Intern Med</source><year>2018</year>;<volume>169</volume>:<fpage>543</fpage>-<lpage>53</lpage>. <pub-id pub-id-type="doi">10.7326/M18-0808</pub-id><pub-id pub-id-type="pmid">30304368</pub-id></mixed-citation></ref><ref id="r8"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>K</given-names></name><name name-style="western"><surname>Liu</surname><given-names>W</given-names></name><name name-style="western"><surname>Liang</surname><given-names>H</given-names></name></person-group>. <article-title>Effect of statins on sepsis and inflammatory factors: A Mendelian randomization study.</article-title><source>Eur J Clin Invest</source><year>2024</year>;<volume>54</volume>:<elocation-id>e14164</elocation-id>. <pub-id pub-id-type="doi">10.1111/eci.14164</pub-id><pub-id pub-id-type="pmid">38229409</pub-id></mixed-citation></ref><ref id="r9"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ando</surname><given-names>H</given-names></name><name name-style="western"><surname>Takamura</surname><given-names>T</given-names></name><name name-style="western"><surname>Ota</surname><given-names>T</given-names></name><etal/></person-group><article-title>Cerivastatin improves survival of mice with lipopolysaccharide-induced sepsis.</article-title><source>J Pharmacol Exp Ther</source><year>2000</year>;<volume>294</volume>:<fpage>1043</fpage>-<lpage>6</lpage>.<pub-id pub-id-type="pmid">10945857</pub-id></mixed-citation></ref><ref id="r10"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>S</given-names></name><name name-style="western"><surname>Rahman</surname><given-names>M</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>S</given-names></name><etal/></person-group><article-title>Simvastatin antagonizes CD40L secretion, CXC chemokine formation, and pulmonary infiltration of neutrophils in abdominal sepsis.</article-title><source>J Leukoc Biol</source><year>2011</year>;<volume>89</volume>:<fpage>735</fpage>-<lpage>42</lpage>. <pub-id pub-id-type="doi">10.1189/jlb.0510279</pub-id><pub-id pub-id-type="pmid">21330348</pub-id></mixed-citation></ref><ref id="r11"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Spitzer</surname><given-names>AL</given-names></name><name name-style="western"><surname>Harris</surname><given-names>HW</given-names></name></person-group>. <article-title>Statins attenuate sepsis.</article-title><source>Surgery</source><year>2006</year>;<volume>139</volume>:<fpage>283</fpage>-<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1016/j.surg.2005.08.029</pub-id><pub-id pub-id-type="pmid">16546490</pub-id></mixed-citation></ref><ref id="r12"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yasuda</surname><given-names>H</given-names></name><name name-style="western"><surname>Yuen</surname><given-names>PS</given-names></name><name name-style="western"><surname>Hu</surname><given-names>X</given-names></name><etal/></person-group><article-title>Simvastatin improves sepsis-induced mortality and acute kidney injury via renal vascular effects.</article-title><source>Kidney Int</source><year>2006</year>;<volume>69</volume>:<fpage>1535</fpage>-<lpage>42</lpage>. <pub-id pub-id-type="doi">10.1038/sj.ki.5000300</pub-id><pub-id pub-id-type="pmid">16557230</pub-id><pub-id pub-id-type="pmcid">PMC2377392</pub-id></mixed-citation></ref><ref id="r13"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tavakkoli</surname><given-names>A</given-names></name><name name-style="western"><surname>Johnston</surname><given-names>TP</given-names></name><name name-style="western"><surname>Sahebkar</surname><given-names>A</given-names></name></person-group>. <article-title>Antifungal effects of statins.</article-title><source>Pharmacol Ther</source><year>2020</year>;<volume>208</volume>:<elocation-id>107483</elocation-id>. <pub-id pub-id-type="doi">10.1016/j.pharmthera.2020.107483</pub-id><pub-id pub-id-type="pmid">31953128</pub-id></mixed-citation></ref><ref id="r14"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bhattacharya</surname><given-names>S</given-names></name><name name-style="western"><surname>Esquivel</surname><given-names>BD</given-names></name><name name-style="western"><surname>White</surname><given-names>TC</given-names></name></person-group>. <article-title>Overexpression or Deletion of Ergosterol Biosynthesis Genes Alters Doubling Time, Response to Stress Agents, and Drug Susceptibility in Saccharomyces cerevisiae.</article-title><source>mBio</source><year>2018</year>;<volume>9</volume>:<elocation-id>e01291-18</elocation-id>. <pub-id pub-id-type="doi">10.1128/mBio.01291-18</pub-id><pub-id pub-id-type="pmid">30042199</pub-id><pub-id pub-id-type="pmcid">PMC6058291</pub-id></mixed-citation></ref><ref id="r15"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Oesterle</surname><given-names>A</given-names></name><name name-style="western"><surname>Laufs</surname><given-names>U</given-names></name><name name-style="western"><surname>Liao</surname><given-names>JK</given-names></name></person-group>. <article-title>Pleiotropic Effects of Statins on the Cardiovascular System.</article-title><source>Circ Res</source><year>2017</year>;<volume>120</volume>:<fpage>229</fpage>-<lpage>43</lpage>. <pub-id pub-id-type="doi">10.1161/CIRCRESAHA.116.308537</pub-id><pub-id pub-id-type="pmid">28057795</pub-id><pub-id pub-id-type="pmcid">PMC5467317</pub-id></mixed-citation></ref><ref id="r16"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Haas</surname><given-names>H.</given-names></name></person-group><article-title>Fungal siderophore metabolism with a focus on Aspergillus fumigatus.</article-title><source>Nat Prod Rep</source><year>2014</year>;<volume>31</volume>:<fpage>1266</fpage>-<lpage>76</lpage>. <pub-id pub-id-type="doi">10.1039/c4np00071d</pub-id><pub-id pub-id-type="pmid">25140791</pub-id><pub-id pub-id-type="pmcid">PMC4162504</pub-id></mixed-citation></ref><ref id="r17"><label>17</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nagy</surname><given-names>G</given-names></name><name name-style="western"><surname>Vaz</surname><given-names>AG</given-names></name><name name-style="western"><surname>Szebenyi</surname><given-names>C</given-names></name><etal/></person-group><article-title>CRISPR-Cas9-mediated disruption of the HMG-CoA reductase genes of Mucor circinelloides and subcellular localization of the encoded enzymes.</article-title><source>Fungal Genet Biol</source><year>2019</year>;<volume>129</volume>:<fpage>30</fpage>-<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1016/j.fgb.2019.04.008</pub-id><pub-id pub-id-type="pmid">30991115</pub-id></mixed-citation></ref><ref id="r18"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Magwenzi</surname><given-names>S</given-names></name><name name-style="western"><surname>Woodward</surname><given-names>C</given-names></name><name name-style="western"><surname>Wraith</surname><given-names>KS</given-names></name><etal/></person-group><article-title>Oxidized LDL activates blood platelets through CD36/NOX2-mediated inhibition of the cGMP/protein kinase G signaling cascade.</article-title><source>Blood</source><year>2015</year>;<volume>125</volume>:<fpage>2693</fpage>-<lpage>703</lpage>. <pub-id pub-id-type="doi">10.1182/blood-2014-05-574491</pub-id><pub-id pub-id-type="pmid">25710879</pub-id><pub-id pub-id-type="pmcid">PMC4408294</pub-id></mixed-citation></ref><ref id="r19"><label>19</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hotchkiss</surname><given-names>RS</given-names></name><name name-style="western"><surname>Karl</surname><given-names>IE</given-names></name></person-group>. <article-title>The pathophysiology and treatment of sepsis.</article-title><source>N Engl J Med</source><year>2003</year>;<volume>348</volume>:<fpage>138</fpage>-<lpage>50</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMra021333</pub-id><pub-id pub-id-type="pmid">12519925</pub-id></mixed-citation></ref><ref id="r20"><label>20</label><mixed-citation publication-type="data">Johnson A, Bulgarelli L, Pollard T, et al. Mimic-IV (Version1.0). PhysioNet. 2021. Available online: https://doi.org/<pub-id pub-id-type="doi">10.13026/s6n6-xd98</pub-id></mixed-citation></ref><ref id="r21"><label>21</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Haneuse</surname><given-names>S</given-names></name><name name-style="western"><surname>VanderWeele</surname><given-names>TJ</given-names></name><name name-style="western"><surname>Arterburn</surname><given-names>D</given-names></name></person-group>. <article-title>Using the E-Value to Assess the Potential Effect of Unmeasured Confounding in Observational Studies.</article-title><source>JAMA</source><year>2019</year>;<volume>321</volume>:<fpage>602</fpage>-<lpage>3</lpage>. <pub-id pub-id-type="doi">10.1001/jama.2018.21554</pub-id><pub-id pub-id-type="pmid">30676631</pub-id></mixed-citation></ref><ref id="r22"><label>22</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Christensen</surname><given-names>S</given-names></name><name name-style="western"><surname>Thomsen</surname><given-names>RW</given-names></name><name name-style="western"><surname>Johansen</surname><given-names>MB</given-names></name><etal/></person-group><article-title>Preadmission statin use and one-year mortality among patients in intensive care - a cohort study.</article-title><source>Crit Care</source><year>2010</year>;<volume>14</volume>:<fpage>R29</fpage>. <pub-id pub-id-type="doi">10.1186/cc8902</pub-id><pub-id pub-id-type="pmid">20214779</pub-id><pub-id pub-id-type="pmcid">PMC2887131</pub-id></mixed-citation></ref><ref id="r23"><label>23</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kyu Oh</surname><given-names>T</given-names></name><name name-style="western"><surname>Song</surname><given-names>IA</given-names></name><name name-style="western"><surname>Lee</surname><given-names>JH</given-names></name><etal/></person-group><article-title>Preadmission Statin Use and 90-day Mortality in the Critically Ill: A Retrospective Association Study.</article-title><source>Anesthesiology</source><year>2019</year>;<volume>131</volume>:<fpage>315</fpage>-<lpage>27</lpage>. <pub-id pub-id-type="doi">10.1097/ALN.0000000000002811</pub-id><pub-id pub-id-type="pmid">31246609</pub-id></mixed-citation></ref><ref id="r24"><label>24</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yao</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>X</given-names></name><name name-style="western"><surname>Wang</surname><given-names>M</given-names></name><etal/></person-group><article-title>Association between the use of statins and in-hospital mortality risk in patients with sepsis-induced coagulopathy during ICU stays: a study based on medical information mart for intensive care database.</article-title><source>BMC Infect Dis</source><year>2024</year>;<volume>24</volume>:<fpage>738</fpage>. <pub-id pub-id-type="doi">10.1186/s12879-024-09636-y</pub-id><pub-id pub-id-type="pmid">39061029</pub-id><pub-id pub-id-type="pmcid">PMC11282707</pub-id></mixed-citation></ref><ref id="r25"><label>25</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mao</surname><given-names>H</given-names></name><name name-style="western"><surname>Yu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Q</given-names></name><etal/></person-group><article-title>Association between pre-ICU statin use and ARDS mortality in the MIMIC-IV database: a cohort study.</article-title><source>Front Med (Lausanne)</source><year>2023</year>;<volume>10</volume>:<elocation-id>1328636</elocation-id>. <pub-id pub-id-type="doi">10.3389/fmed.2023.1328636</pub-id><pub-id pub-id-type="pmid">38188328</pub-id><pub-id pub-id-type="pmcid">PMC10768014</pub-id></mixed-citation></ref><ref id="r26"><label>26</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shi</surname><given-names>XT</given-names></name><name name-style="western"><surname>Yan</surname><given-names>LJ</given-names></name><name name-style="western"><surname>Lu</surname><given-names>FY</given-names></name><etal/></person-group><article-title>Exploring the therapeutic potential of simvastatin in pancreatic neuroendocrine neoplasms: insights into cell cycle regulation and apoptosis.</article-title><source>Transl Cancer Res</source><year>2024</year>;<volume>13</volume>:<fpage>4315</fpage>-<lpage>23</lpage>. <pub-id pub-id-type="doi">10.21037/tcr-24-363</pub-id><pub-id pub-id-type="pmid">39262466</pub-id><pub-id pub-id-type="pmcid">PMC11384313</pub-id></mixed-citation></ref><ref id="r27"><label>27</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>J</given-names></name><name name-style="western"><surname>Cao</surname><given-names>G</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Mendelian randomization study on simvastatin and gastric cancer: exploring the therapeutic potential of statins in oncology.</article-title><source>Transl Cancer Res</source><year>2024</year>;<volume>13</volume>:<fpage>4671</fpage>-<lpage>7</lpage>. <pub-id pub-id-type="doi">10.21037/tcr-24-576</pub-id><pub-id pub-id-type="pmid">39430821</pub-id><pub-id pub-id-type="pmcid">PMC11483371</pub-id></mixed-citation></ref><ref id="r28"><label>28</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Papazian</surname><given-names>L</given-names></name><name name-style="western"><surname>Roch</surname><given-names>A</given-names></name><name name-style="western"><surname>Charles</surname><given-names>PE</given-names></name><etal/></person-group><article-title>Effect of statin therapy on mortality in patients with ventilator-associated pneumonia: a randomized clinical trial.</article-title><source>JAMA</source><year>2013</year>;<volume>310</volume>:<fpage>1692</fpage>-<lpage>700</lpage>. <pub-id pub-id-type="doi">10.1001/jama.2013.280031</pub-id><pub-id pub-id-type="pmid">24108510</pub-id></mixed-citation></ref><ref id="r29"><label>29</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>M</given-names></name><name name-style="western"><surname>Ji</surname><given-names>M</given-names></name><name name-style="western"><surname>Si</surname><given-names>X</given-names></name></person-group>. <article-title>The effects of statin therapy on mortality in patients with sepsis: A meta-analysis of randomized trials.</article-title><source>Medicine (Baltimore)</source><year>2018</year>;<volume>97</volume>:<elocation-id>e11578</elocation-id>. <pub-id pub-id-type="doi">10.1097/MD.0000000000011578</pub-id><pub-id pub-id-type="pmid">30075526</pub-id><pub-id pub-id-type="pmcid">PMC6081129</pub-id></mixed-citation></ref><ref id="r30"><label>30</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Feng</surname><given-names>Y.</given-names></name></person-group><article-title>Efficacy of statin therapy in patients with acute respiratory distress syndrome/acute lung injury: a systematic review and meta-analysis.</article-title><source>Eur Rev Med Pharmacol Sci</source><year>2018</year>;<volume>22</volume>:<fpage>3190</fpage>-<lpage>8</lpage>. <pub-id pub-id-type="doi">10.26355/eurrev_201805_15080</pub-id><pub-id pub-id-type="pmid">29863265</pub-id></mixed-citation></ref></ref-list></back><sub-article id="jtd-17-01-429-prf" article-type="reviewer-report"><front-stub><title-group><article-title>Peer Review File</article-title></title-group></front-stub><body><p>Available at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://jtd.amegroups.com/article/view/10.21037/jtd-2024-2243/prf" ext-link-type="uri">https://jtd.amegroups.com/article/view/10.21037/jtd-2024-2243/prf</ext-link></p><fig id="d67e2176" position="anchor" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jtd-17-01-429-prf.pdf" position="float" orientation="portrait"/></fig></body></sub-article></article></pmc-articleset>